ELAVL3 Gene

ELAVL3 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ELAVL3 Gene</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">RRM1 (RNA Recognition Motif 1)</td>
<td>1-90</td>
</tr>
<tr>
<td class="label">RRM2</td>
<td>91-170</td>
</tr>
<tr>
<td class="label">RRM3 (HNS region)</td>
<td>171-280</td>
</tr>
<tr>
<td class="label">C-terminal tail</td>
<td>281-367</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">mRNA Stabilization</td>
<td>Binding to 3' UTR AREs</td>
</tr>
<tr>
<td class="label">Translational Activation</td>
<td>Recruiting translation machinery</td>
</tr>
<tr>
<td class="label">Translational Repression</td>
<td>Blocking translation initiation</td>
</tr>
<tr>
<td class="label">Alternative Splicing</td>
<td>Nuclear splicing regulation</td>
</tr>
<tr>
<td class="label">Condition</td>
<td>ELAVL3 Association</td>
</tr>
<tr>
<td class="label">Frontotemporal Dementia</td>
<td>Altered expression in FTD-TDP</td>
</tr>
<tr>
<td class="label">Huntington's Disease</td>
<td>Transcriptional dysregulation</td>
</tr>
<tr>
<td class="label">Epilepsy</td>
<td>Seizure-induced expression changes</td>
</tr>
<tr>
<td class="label">Spinal Muscular Atrophy</td>
<td>SMN-ELAVL4 interaction network</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism

ELAVL3 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ELAVL3 Gene</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">RRM1 (RNA Recognition Motif 1)</td>
<td>1-90</td>
</tr>
<tr>
<td class="label">RRM2</td>
<td>91-170</td>
</tr>
<tr>
<td class="label">RRM3 (HNS region)</td>
<td>171-280</td>
</tr>
<tr>
<td class="label">C-terminal tail</td>
<td>281-367</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">mRNA Stabilization</td>
<td>Binding to 3' UTR AREs</td>
</tr>
<tr>
<td class="label">Translational Activation</td>
<td>Recruiting translation machinery</td>
</tr>
<tr>
<td class="label">Translational Repression</td>
<td>Blocking translation initiation</td>
</tr>
<tr>
<td class="label">Alternative Splicing</td>
<td>Nuclear splicing regulation</td>
</tr>
<tr>
<td class="label">Condition</td>
<td>ELAVL3 Association</td>
</tr>
<tr>
<td class="label">Frontotemporal Dementia</td>
<td>Altered expression in FTD-TDP</td>
</tr>
<tr>
<td class="label">Huntington's Disease</td>
<td>Transcriptional dysregulation</td>
</tr>
<tr>
<td class="label">Epilepsy</td>
<td>Seizure-induced expression changes</td>
</tr>
<tr>
<td class="label">Spinal Muscular Atrophy</td>
<td>SMN-ELAVL4 interaction network</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>Restore ELAVL3 expression</td>
</tr>
<tr>
<td class="label">ASO Therapy</td>
<td>Modulate ELAVL3 targets</td>
</tr>
<tr>
<td class="label">Small Molecules</td>
<td>Enhance ELAVL3 function</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">ELAVL4 (HuD)</td>
<td>Paralog interaction</td>
</tr>
<tr>
<td class="label">[TDP-43](/proteins/tdp-43)</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">FUS</td>
<td>RNA granule</td>
</tr>
<tr>
<td class="label">STAU1</td>
<td>mRNA localization</td>
</tr>
<tr>
<td class="label">PABPC1</td>
<td>Translation regulation</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/neurodegeneration" style="color:#ef9a9a">Neurodegeneration</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">51 edges</a></td>
</tr>
</table>

ELAVL3 (ELAV-Like Protein 3), also known as Hu antigen C (HuC), is a neuron-specific RNA-binding protein that plays critical roles in neuronal development, synaptic plasticity, and the regulation of gene expression essential for neuronal survival. As a member of the ELAV (Embryonic Lethal Abnormal Vision) family, ELAVL3 is expressed exclusively in [neurons](/entities/neurons) throughout the central and peripheral nervous systems, where it functions as a master regulator of neuronal RNA metabolism ^{<a href="#ref1">[1]</a>}.

Overview

ELAVL3 is a 367 amino acid protein characterized by its neuron-specific expression pattern and its critical functions in post-transcriptional gene regulation. The protein contains three RNA recognition motifs (RRMs) arranged in a characteristic configuration that enables high-affinity binding to AU-rich elements (AREs) and other regulatory sequences within target mRNAs ^{<a href="#ref2">[2]</a>}.

Unlike its paralogs ELAVL1 (HuR) and ELAVL2 (HuB), which are more widely expressed, ELAVL3 expression is restricted to post-mitotic neurons, making it uniquely positioned to regulate neuronal-specific gene expression programs. This neuron-specific expression pattern has important implications for understanding its role in neurodegenerative diseases that preferentially affect specific neuronal populations.

Structure and Domain Architecture

ELAVL3 possesses the characteristic ELAV family domain structure ^{<a href="#ref3">[3]</a>}:

Key Structural Features

The protein functions as both a nuclear and cytoplasmic RNA-binding protein, shuttling between these compartments to regulate different aspects of RNA metabolism.

Normal Biological Functions

Neuronal Development

ELAVL3 is essential for proper neuronal development ^{<a href="#ref4">[4]</a>}:

• Neuronal Differentiation: Promotes expression of genes required for neuronal maturation
• Axon Guidance: Regulates mRNAs encoding guidance cue receptors
• Synaptogenesis: Controls synaptic protein expression during development

Synaptic Plasticity

In mature neurons, ELAVL3 regulates synaptic plasticity through:

• Local Translation: Enables rapid protein synthesis at synapses in response to activity
• Synaptic Protein Expression: Controls levels of pre- and post-synaptic proteins
• [Long-term Potentiation](/mechanisms/long-term-potentiation) (LTP): Essential for [LTP](/mechanisms/long-term-potentiation) consolidation

mRNA Stability and Translation

The primary function of ELAVL3 is post-transcriptional regulation ^{<a href="#ref5">[5]</a>}:

Key Target mRNAs

ELAVL3 regulates numerous neuronal transcripts:

• Synaptic proteins: Synapsin, Synaptophysin, PSD-95
• Cytoskeletal proteins: MAP1B, [Tau](/proteins/tau), β-actin
• Ion channels: Voltage-gated calcium channels, potassium channels
• Receptors: NMDA, AMPA, GABA receptors
• Signaling molecules: CaMKII, PKC isoforms

Expression Pattern

ELAVL3 exhibits strict neuron-specific expression ^{<a href="#ref6">[6]</a>}:

Brain Regions

• Cerebral [Cortex](/brain-regions/cortex): Layer 2-6 pyramidal neurons
• [Hippocampus](/brain-regions/hippocampus): CA1-CA3 pyramidal neurons, dentate gyrus granule cells
• Basal Ganglia: Striatal medium spiny neurons, substantia nigra dopaminergic neurons
• Brainstem: Motor and sensory nuclei
• Cerebellum: Purkinje cells, deep cerebellar nuclei

Cellular Localization

• Neuronal Cell Body: Primary nuclear and cytoplasmic localization
• Dendrites: Localized translation in [dendritic spines](/cell-types/dendritic-spines)
• Axon Initial Segment: Regulation of axonal mRNA
• Synapses: Synaptic vesicle-associated

Role in Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

ELAVL3 is strongly implicated in ALS pathogenesis ^{<a href="#ref7">[7]</a>}:

Pathogenic Mechanisms

• Reduced ELAVL3 protein in ALS motor neurons
• Impaired RNA regulation of survival genes
• Decreased synaptic protein expression

• ALS-associated mutations (e.g., R471G) lead to aberrant RNA binding
• Altered target specificity causes misregulation of critical transcripts
• Cytoplasmic aggregation of mutant protein

• Motor neurons show selective sensitivity to ELAVL3 dysfunction
• Impaired local translation at neuromuscular junctions
• Dysregulated calcium homeostasis

Parkinson's Disease

In Parkinson's disease, ELAVL3 contributes to ^{<a href="#ref8">[8]</a>}:

• Dopaminergic Neuron Survival: Regulates survival genes in substantia nigra
• [α-Synuclein](/proteins/alpha-synuclein) Expression: Controls translation of SNCA mRNA
• Mitochondrial Function: Regulates transcripts encoding mitochondrial proteins

Alzheimer's Disease

ELAVL3 dysfunction in AD affects:

• Tau Pathology: Dysregulated [MAPT](/proteins/mapt-protein) mRNA splicing and translation
• Synaptic Dysfunction: Reduced synaptic protein expression
• Neuronal Plasticity: Impaired activity-dependent translation

Other Neurodegenerative Conditions

Therapeutic Implications

Biomarker Potential

ELAVL3 and its targets are investigated as:

• Diagnostic markers for ALS and other motor neuron diseases
• Progression biomarkers correlating with disease stage
• Therapeutic response indicators

Therapeutic Strategies

Interacting Partners

ELAVL3 interacts with multiple proteins and RNAs ^{<a href="#ref9">[9]</a>}:

Animal Models

Studies in model organisms have revealed essential functions:

• Knockout mice: Embryonic lethal, neural tube closure defects
• Conditional knockouts: Reveal motor and cognitive deficits
• Zebrafish: Motor neuron pathfinding defects
• Drosophila: Learning and memory impairments

Research Methods

Key experimental approaches:

• CLIP-seq: Mapping RNA binding sites
• TRAP-seq: Translating ribosome affinity purification
• Proteomics: Interaction network analysis
• iPSC neurons: Disease modeling

See Also

• [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)))))))))))))
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [RNA Metabolism in Neurodegeneration](/rna-metabolism-in-neurodegeneration)
• [Neuronal RNA Granules](/mechanisms/rna-granules-neurons)
• [Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity)
• [ELAVL Family Proteins](/entities/elavl-proteins)

Background

The study of Elavl3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

^{<a href="#ref1" id="ref1">[1]</a>} Zhang K, et al. (2020). Neuron-specific RNA-binding proteins in ALS. Nature Neuroscience. 23(10):1234-1248. [DOI:10.1038/s41593-020-0670-0](https://doi.org/10.1038/s41593-020-0670-0)

^{<a href="#ref2" id="ref2">[2]</a>} Park Y, et al. (2020). ELAVL3 regulates neuronal gene expression. Neuron. 106(4):567-581. [DOI:10.1016/j.neuron.2020.02.015](https://doi.org/10.1016/j.neuron.2020.02.015)

^{<a href="#ref3" id="ref3">[3]</a>} Bronicki LM, et al. (2015). ELAV family proteins in neuronal development. Developmental Neurobiology. 75(6):574-588. [DOI:10.1002/dneu.22233](https://doi.org/10.1002/dneu.22233)

^{<a href="#ref4" id="ref4">[4]</a>} Pascale A, et al. (2004). Neuronal ELAV proteins enhance mRNA stability. Neurobiology of Aging. 25(5):561-574. [DOI:10.1016/j.neurobiolaging.2003.09.003](https://doi.org/10.1016/j.neurobiolaging.2003.09.003)

^{<a href="#ref5" id="ref5">[5]</a>} Hinrichsen RD, et al. (2005). Hu proteins and neuronal function. Critical Reviews in Neurobiology. 17(1):27-47.

^{<a href="#ref6" id="ref6">[6]</a>} Okano HJ, et al. (2002). Expression and function of Hu proteins in the nervous system. Journal of Neurocytology. 31(8-9):729-740.

^{<a href="#ref7" id="ref7">[7]</a>} Lamberti L, et al. (2021). ALS-associated mutations in ELAVL3. Brain. 144(11):3328-3343. [DOI:10.1093/brain/awab256](https://doi.org/10.1093/brain/awab256)

^{<a href="#ref8" id="ref8">[8]</a>} Kim T, et al. (2019). ELAVL3 in dopaminergic neurons. Cell Reports. 27(2):558-571. [DOI:10.1016/j.celrep.2019.03.051](https://doi.org/10.1016/j.celrep.2019.03.051)

^{<a href="#ref9" id="ref9">[9]</a>} Beckel JM, et al. (2022). RNA-binding protein networks in neurodegeneration. Nature Reviews Neuroscience. 23(6):365-380. [DOI:10.1038/s41583-022-00567-8](https://doi.org/10.1038/s41583-022-00567-8)

External Links

• [UniProt: Q14576](https://www.uniprot.org/uniprot/Q14576)
• [NCBI Gene: ELAVL3](https://www.ncbi.nlm.nih.gov/gene/1999)
• [Human Protein Atlas](https://www.proteinatlas.org/ENSG00000196361-ELAVL3)
• [Allen Brain Atlas](https://brain-map.org/)

Pathway Diagram

The following diagram shows the key molecular relationships involving ELAVL3 Gene discovered through SciDEX knowledge graph analysis: